Press release
Spinal Cord Injury Market Size in 7MM is Anticipated to See a Significant Change | Major Companies- AbbVie, Nipro Corporation, Neurofix, and Others
Spinal Cord Injury Market
The Spinal Cord Injury market report provides current treatment practices, Spinal Cord Injury emerging drugs, Spinal Cord Injury market share of the individual therapies, current and forecasted Spinal Cord Injury market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Spinal Cord Injury treatment practice/algorithm, Spinal Cord Injury market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Spinal Cord Injury market.
Key takeaways from the Spinal Cord Injury Market Research Report
• According to DelveInsight, the Spinal Cord Injury market in 7MM is expected to witness a major change in the study period 2019-2032.
• In 2022, total Spinal Cord Injury diagnosed cases in the US was assessed to be ~326,000 which is expected to increase in the forecast period.
• Males are affected more as compared to females, in case of Spinal Cord Injury.
• The leading Spinal Cord Injury Companies include StemCyte, Lineage Cell Therapeutics (NYSE: LCTX), Kringle Pharma, AbbVie (NYSE: ABBV), Nipro Corporation, ReNetX Bio, Inc., Neurofix, Eli Lilly and Company (NYSE: LLY), ICOS Corporation (NYSE: ICOS), Eusol Biotech Co Ltd, Moleac Pte Ltd., Kringle Pharma Inc, Acorda Therapeutics (NYSE: ACOR), Bayer, GlaxoSmithKline (NYSE: GSK), Pfizer (NYSE: PFE), and others.
• Promising Spinal Cord Injury Pipeline Therapies include Denosumab (Prolia), pregabalin, Vardenafil (Levitra, BAY38-9456), Fampridine-SR, KP-100IT, NeuroAiD, ES135, tadalafil, and others.
Discover more about therapies set to grab major Spinal Cord Injury Market Share @ Spinal Cord Injury Market Size- https://www.delveinsight.com/report-store/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Spinal Cord Injury Overview
Spinal cord injury (SCI) is a serious medical condition that causes the functional, psychological, and socioeconomic disorders. Long-term, secondary medical complications are common and play an important role in the continuum of care for patients with SCI. Complications are a frequent cause of morbidity and mortality and lead to increased rates of re-hospitalization, loss of employability, and decreased quality of life.
Spinal Cord Injury Epidemiology Segmentation in the 7MM
• Total Spinal Cord Injury Cases
• Spinal Cord Injury Gender-specific Cases
• Spinal Cord Injury Cause-specific Cases
• Spinal Cord Injury Diagnosed Cases
• Total Spinal Cord Injury Cases at Neurological Level
Recent Developmental Activities in the Spinal Cord Injury Treatment Landscape
• KP-100IT (Kringle Pharma) is an HGF that has been shown to exhibit a wide variety of physiological activities, not only as a mitogenic factor for liver cells but also as mitogenic, anti-apoptotic (cell death), morphogenic, and angiogenic factors for various other types of cells. Currently, the company is assessing KP-100IT in a Phase III clinical study in Subjects with acute spinal cord injury.
• NEURO-CELLS (Neuroplast) are derived from the bone marrow of the patient itself. The company's technology calls on the self-healing capacity of non-manipulated stem cells, that the body itself is unable to leverage for neurodegenerative conditions due to the blood brain barrier. The EU has granted stem cell specialist Neuroplast orphan disease designation for traumatic spinal cord injury and fast-track development pathway for traumatic spinal cord injury (TSCI). Currently, the company is conducting Phase II/III clinical study of NEURO-CELLS to assess its efficacy and safety in (sub)acute spinal cord injury patients.
• ABT-555 (Abbvie) is a monoclonal antibody of the human immunoglobulin (Ig)G1 isotype that binds selectively to repulsive guidance molecule A (RGMa). ABT-555 (elezanumab) is being investigated to treat spinal cord injuries and acute ischemic stroke. RGMa is an inhibitor of axonal outgrowth and recognized as an important factor in inhibiting neuronal regeneration and functional recovery following central nervous system (CNS) damage. Elezanumab is being investigated to treat spinal cord injuries, multiple sclerosis and acute ischemic stroke. AbbVie has received orphan drug and fast track designations from the US FDA for ABT-555 (elezanumab) to treat spinal cord injury (SCI). Currently, the drug is being studied in Phase II clinical study to assess the safety and efficacy in acute traumatic cervical spinal cord injury.
• MT-3921 (Mitsubishi Tanabe Pharma) is a novel humanized immunoglobulin G1 (IgG1) monoclonal antibody that binds to repulsive guidance molecule A(RGMa). In July 2021, the US FDA granted fast track designation to MT-3921 for the treatment of spinal cord injury. Currently, the company is assessing the efficacy and safety of MT-3921 in Phase II of clinical development in subjects with acute traumatic cervical spinal cord injury.
• AST-OPC1 (Lineage Cell Therapeutics) is an oligodendrocyte progenitor cell therapy that is currently in a Phase I/IIa multicenter clinical trial for acute spinal cord injuries (SCI). OPC1 has received a regenerative medicine advanced therapy (RMAT) and from the FDA, which include accelerated programs intended to facilitate the development and review process, including early interactions with US FDA during clinical development and enhanced favorability for marketing approval. Recently, in March 2023, the company announced its plans for a Type B meeting with FDA to discuss about amendment to the IND application for OPC 1 enabling clinical testing of a novel spinal cord delivery system in the second quarter of 2023.
Download the report to understand which factors are driving Spinal Cord Injury Epidemiology Trends @ Spinal Cord Injury Epidemiological Insights- https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Spinal Cord Injury Market Dynamics
The Spinal Cord Injury market dynamics is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies during the forecast period of 2023-2032.
Spinal Cord Injury Market Landscape
The landscape of Spinal cord injury (CSCI) management is quickly changing as the heterogeneity of patients, and long-term importance of key early interventions are increasingly being recognized. Combinatorial neuro-protective and neuroregenerative strategies are most likely to be effective moving forward given the multifaceted nature of the injury; however, this approach may require tailoring to specific patient subgroups. Overall, the rise in spinal cord injury patient population, increased funding by governmental bodies, and vigorous R&D activities are further expected to propel the SCI market during the forecast period (2023-2032).
To know more about Spinal Cord Injury Treatment options, visit @ Spinal Cord Injury Drugs- https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Spinal Cord Injury Emerging Drugs
• Symptomatic therapies (nifedipine, anticholinergic medications, α-blockers, analgesics, nonsteroidal anti-inflammatory drugs, opioids etc.)
• STEMIRAC (human [autologous] bone marrow derived mesenchymal stem cell): Nipro
• ABT-555 (elezanumab): Abbvie
• KP-100IT: Kringle Pharma
Spinal Cord Injury Key Companies
• StemCyte, Lineage Cell Therapeutics
• Kringle Pharma
• AbbVie
• Nipro Corporation
• ReNetX Bio Inc.
• Neurofix
• Eli Lilly and Company
• ICOS Corporation
• Eusol Biotech Co Ltd
• Moleac Pte Ltd
• Kringle Pharma Inc
• Acorda Therapeutics
• Bayer
• GlaxoSmithKline
• Pfizer
Spinal Cord Injury Pipeline Therapies
• Denosumab (Prolia)
• pregabalin
• Vardenafil (Levitra, BAY38-9456)
• Fampridine-SR
• KP-100IT
• NeuroAiD
• ES135
• Tadalafil
Learn more about the Spinal Cord Injury Pipeline Therapies in clinical trials @ Spinal Cord Injury Treatment Market- https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Spinal Cord Injury Market Research Report
• Coverage- 7MM
• Spinal Cord Injury Companies- StemCyte, Lineage Cell Therapeutics (NYSE: LCTX), Kringle Pharma, AbbVie (NYSE: ABBV), Nipro Corporation, ReNetX Bio, Inc., Neurofix, Eli Lilly and Company (NYSE: LLY), ICOS Corporation (NYSE: ICOS), Eusol Biotech Co Ltd, Moleac Pte Ltd., Kringle Pharma Inc, Acorda Therapeutics (NYSE: ACOR), Bayer, GlaxoSmithKline (NYSE: GSK), Pfizer (NYSE: PFE) and others.
• Spinal Cord Injury Pipeline Therapies- Denosumab (Prolia), pregabalin, Vardenafil (Levitra, BAY38-9456), Fampridine-SR, KP-100IT, NeuroAiD, ES135, tadalafil, and others.
• Spinal Cord Injury Market Dynamics: Spinal Cord Injury Market Drivers and Barriers
• Spinal Cord Injury Market Access and Reimbursement, Unmet Needs, Future Perspectives
Discover more about Spinal Cord Injury Drugs in development @ Spinal Cord Injury Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Executive Summary of Spinal Cord Injury (SCI)
3. Competitive Intelligence Analysis for Spinal Cord Injury (SCI)
4. Spinal Cord Injury (SCI): Market Overview at a Glance
5. Spinal Cord Injury (SCI): Disease Background and Overview
6. Patient Journey
7. Spinal Cord Injury (SCI) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Spinal Cord Injury (SCI) Unmet Needs
10. Key Endpoints of Spinal Cord Injury (SCI) Treatment
11. Spinal Cord Injury (SCI) Marketed Products
12. Spinal Cord Injury (SCI) Emerging Therapies
13. Spinal Cord Injury (SCI): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Spinal Cord Injury Market Outlook
16. Access and Reimbursement Overview of Spinal Cord Injury (SCI)
17. KOL Views
18. Spinal Cord Injury Market Drivers
19. Spinal Cord Injury Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Get in touch with our Business executive @ Spinal Cord Injury Market Drivers and Barriers- https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Published Important Links-
https://onlyfans.com/dennydones9
https://maker.wiznet.io/dennydones9
https://collab.sundance.org/people/Denny-Dones-1699939772
https://insurtechasia.mn.co/posts/45403575
https://meganto-lottery.mn.co/posts/45403650
https://ylimun.mn.co/posts/45403740
https://network-79379.mn.co/posts/45404061
https://acatpg.mn.co/posts/45404422
https://brooklynneo.mn.co/posts/45404495
https://ucat-bootcamp.mn.co/posts/45404540
https://coding-playground.mn.co/posts/45404600
https://living-word-network.mn.co/posts/45404653
https://www.storeboard.com/JohnSmith-5965202
https://doodleordie.com/profile/dennydones99
https://macro.market/company/delveinsight-business-research
https://pantip.com/profile/7306022#topics
https://allmylinks.com/dennydonesusa
https://uconnect.ae/read-blog/4382
https://blacksnetwork.net/post/102497_herpetic-keratitis-is-a-condition-that-affects-the-eye-and-is-caused-by-the-herp.html
https://ekonty.com/-dennydones99
https://app.wedonthavetime.org/posts/03e285b9-e449-4c96-b257-8cb7a2b74243
https://www.weddingbee.com/members/dennydones99/
https://community.storytellingwithdata.com/members/me/gallery
https://participer.valdemarne.fr/profiles/denny_dones/activity
https://elderassociation.mn.co/posts/45117025
https://www.domestika.org/en/dennydones99
https://nxgen.mn.co/members/19995548
https://www.laclt.com/profile/ybhardwaj/profile
https://stemfemmes.mn.co/posts/emerging-trends-in-managing-hot-flashes-in-the-prostate-cancer-market
https://network-91053.mn.co/posts/45119865
https://autism-support.mn.co/posts/understanding-hot-flashes-in-prostate-cancer-market-size-and-outlook-2032
https://jasa-seo.mn.co/posts/45120226
https://lapp.unl.edu.ec/profiles/dennydones99/activity?locale=en
https://imarticus.org/skillenza/user/dennydones9
https://oppathingzz.mn.co/members/20019648
https://findaspring.org/members/dennydones9/
https://www.poeticous.com/yashveer-bhardwaj
https://git.disroot.org/dennydones9
https://kuula.co/profile/havensmith
https://artmight.com/user/profile/3082810
https://www.credly.com/users/denny-dones/badges
https://quantum-buoyancy.mn.co/posts/axillary-hyperhidrosis-market-size-and-outlook-delveinsight
https://freeline.mn.co/posts/45202136
https://3dwarehouse.sketchup.com/user/0e9f9584-794e-4467-ac59-79db9efbadd9/Denny-Dones
https://www.hackster.io/dennydones9
https://letterboxd.com/dennydones9/
https://ko-fi.com/dennydones9
https://wakelet.com/@DennyDones813
https://onedio.com/profil/dennydones9
https://www.lyrics.com/user/349564/dennydones9#google_vignette
https://hypothes.is/users/dennydones9
https://shivambhu-hut.mn.co/posts/exploring-the-axillary-hyperhidrosis-market-innovations-treatments-and-future-prospects
https://zumvu.com/dennydones9/
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Spinal Cord Injury Market Size in 7MM is Anticipated to See a Significant Change | Major Companies- AbbVie, Nipro Corporation, Neurofix, and Others here
News-ID: 3287155 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Spinal
Evolving Market Trends In The Spinal Fusion Devices Industry: Advancements In Sp …
The Spinal Fusion Devices Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]._x000D_
_x000D_
What Is the Expected Spinal Fusion Devices Market Size During the Forecast Period?_x000D_
Over the past few years, there has been a significant growth in the spinal fusion devices market. The market is projected…
Key Influencer in the Spinal Fusion Devices Market 2025: Rising Spinal Disorder …
What Is the Forecasted Market Size and Growth Rate for the Spinal Fusion Devices Market?
The market for spinal fusion devices has experienced significant growth in the past couple of years. Expectations are that it will rise from estimates of $7.85 billion in 2024 to approximately $8.31 billion in 2025, giving us a compound annual growth rate (CAGR) of 5.8%. Factors contributing to this notable expansion during the historical period can…
Disposable Spinal Instrument Market: Revolutionizing Spinal Surgery with Hygiene …
Introduction
The medical device market has witnessed a surge in demand for disposable instruments, especially in areas where hygiene, precision, and efficiency are paramount. One such sector experiencing rapid growth is the disposable spinal instrument market. Spinal surgeries, being intricate and requiring high precision, have traditionally relied on reusable instruments. However, growing concerns about hygiene, infection control, and surgical efficiency have accelerated the shift toward disposable spinal instruments. These devices not…
Endoscopic Spinal Surgery Market: Minimally Invasive Solutions for Spinal Disord …
Global Endoscopic Spinal Surgery Market size was valued at US$ 667 Mn. in 2022 and the total revenue is expected to grow at a CAGR of 7.9% through 2022 to 2029, reaching nearly US$ 1137 Mn.
Endoscopic Spinal Surgery Market Overview:
Maximize Market Research is a research firm that has published a detailed analysis of the "Endoscopic Spinal Surgery Market". MMR in-depth market assessments in research reports consider significant technological advancements in…
Spinal Resilience: Acute Spinal Cord Injury Drug Pipeline Landscape (2023)
Market Outlook:
Charting Progress: Acute Spinal Cord Injury Drug Pipeline Landscape (2023)
The Acute Spinal Cord Injury Drug Pipeline Landscape sets its sights on a decade of advancements poised to redefine the trajectory of spinal resilience. This comprehensive outlook explores the unfolding strategies, innovations, and breakthroughs that promise to revolutionize the landscape of acute spinal cord injury treatment.
Market Drivers:
Neuroregeneration on the Horizon: At the forefront of the Acute Spinal Cord Injury Drug…
Spinal Laminoplasty Market - Revolutionizing spinal care with minimally invasive …
Newark, New Castle, USA: The "Spinal Laminoplasty Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Spinal Laminoplasty Market: https://www.growthplusreports.com/report/spinal-laminoplasty-market/8601
This latest report researches the industry structure, sales, revenue,…
